ArisGlobal signs first ARISg™ customer in China

Mar 7, 2016

Chengdu Institute of Biological Products Co., Ltd. to Strengthens Pharmacovigilance Process using ArisGlobal’s ARISg™ Solution.

Princeton, NJ— 21st January, 2016: ArisGlobal®, a leading provider of software solutions to the life science industry, has announced that Chengdu Institute of Biological Products Co., Ltd. (CDIBP) has selected ARISg™ to strengthen and build a solid foundation for its pharmacovigilance process.

Located in Chengdu, CDIBP (a subsidiary of China National Biotec Group Co., Ltd. (CNBG)) is one of the largest developing and manufacturing bases of vaccines and biological products in China. CDIBP, in partnership with PATH, an international nonprofit focused on improving health, has been working on building a pharmacovigilance database that meets the World Health Organization’s  requirements to provide affordable vaccines to a broader market.

With the implementation of ARISg™, a safety information management system chosen by life sciences companies worldwide, CDIBP  will be able to establish an effective clinical safety and pharmacovigilance system from case data entry to automatic generation of submission-ready adverse event reports that fully support all global regulatory reporting requirements. The system will also be available in the Chinese language to more efficiently support Chinese users.

“It’s a very nice experience to work with ArisGlobal.  They provide us with not only their excellent product, but also their leading expertise in pharmacovigilance systems and first class service to meet customer requirements.” said Mr. Zhang Lei, International Cooperation Project Manager, Chengdu Institute of Biological Products Co., Ltd.

“We are very pleased that CDIBP has selected ARISg™ for  its safety system and will be our first customer in the Chinese Market” said Kazushi Iwai, Business Development Director for North Asia at ArisGlobal KK. “Because of the growing pharmaceutical market in China, combined with a more stringent regulatory environment, meeting an increased demand for expertise in pharmacovigilance practices can be one of the challenges faced by domestic companies and healthcare practitioners.  ArisGlobal’s in-depth knowledge and experience in the pharmacovigilance domain will support CDIBP in implementing and understanding the best practices and requirements that are critically important in drug safety and risk management.”

CDIBP’s ARISg™ safety system will be implemented by ArisGlobal KK, the Japanese subsidiary of ArisGlobal®, located in Tokyo Japan.

 

LATEST NEWS

About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn: linkedin.com/company/aris-global
Follow @Aris_Global on Twitter: twitter.com/aris_global

Contact

Alberto Cantor
ArisGlobal
+1 609-360-4042 | acantor@arisglobal.com